Quest Pharmatech (TSE:QPT) has released an update.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Quest PharmaTech Inc. has refiled its fiscal 2023 financial statements due to a material misstatement in the valuation of OQP Bio bonds, leading to a significant write-down and a non-cash impairment charge. The revised valuation, conducted by an independent third party, reflects a considerably lower fair value for the OQP Bio bonds. Additionally, the company has appointed Mr. Bradley J. Glass as a new director, pending regulatory approval.
For further insights into TSE:QPT stock, check out TipRanks’ Stock Analysis page.